1. Phylogeny  
   Tyrosine-protein kinase JAK2, commonly referred to as Janus kinase 2, is a member of the Janus kinase (JAK) family that also includes JAK1, JAK3, and tyrosine kinase 2 (Tyk2), and is evolutionarily conserved among metazoans. Comparative sequence analyses have demonstrated that the JAK family kinase domains and associated regulatory modules are present in organisms ranging from invertebrates to mammals, indicating an early metazoan origin with conservation of the characteristic domain architecture. JAK2 and its orthologs are found in all mammalian species, reflecting their essential roles in cytokine signaling pathways that regulate hematopoiesis, immune responses, and other fundamental cellular processes (babon2014themolecularregulation pages 1-3, krupa2002therepertoireof pages 5-7). In phylogenetic analyses, JAK2 groups with other non-receptor tyrosine kinases that feature a bipartite catalytic region flanked by regulatory domains. This evolutionary grouping underscores not only its conserved kinase catalytic core but also its unique pairing of a catalytically active kinase domain (JH1) and an adjacent pseudokinase domain (JH2) that evolved to confer autoinhibitory regulation (babon2014themolecularregulation pages 3-4, wilks2008thejakkinases pages 1-1). The conservation of these domains and their sequence motifs across species supports the classification of JAK2 as part of an ancient and indispensable signaling mechanism present in the common ancestor of chordates (babon2014themolecularregulation pages 1-3, krupa2002therepertoireof pages 5-7).
2. Reaction Catalyzed  
   JAK2 catalyzes the transfer of a phosphate group from ATP to specific tyrosine residues on protein substrates. The chemical reaction can be represented as:  
     ATP + protein – Tyr → ADP + protein – phosphotyrosine + H⁺  
   This reaction is central to the propagation of intracellular signals after cytokine receptor activation and is typical of tyrosine kinases. In this reaction, JAK2 utilizes ATP as a phosphate donor, converting it to ADP while phosphorylating tyrosine residues on receptor tails or on downstream signaling molecules such as STAT transcription factors (babon2014themolecularregulation pages 1-3, hubbard2018mechanisticinsightsinto pages 1-2).
3. Cofactor Requirements  
   The catalytic activity of JAK2, like that of most protein kinases, is dependent on the presence of divalent metal ion cofactors, with Mg²⁺ being essential for the efficient binding and proper orientation of ATP within the active site. Mg²⁺ coordinates with the phosphate groups of ATP and stabilizes the transition state during the phosphoryl transfer reaction. This requirement for Mg²⁺ is consistent with the general attributes of tyrosine kinases and has been demonstrated by biochemical studies involving kinase assays (babon2014themolecularregulation pages 1-3, wilks2008thejakkinases pages 5-6).
4. Substrate Specificity  
   JAK2 exhibits substrate specificity that is essential for its role in cytokine signaling. It primarily phosphorylates tyrosine residues located within the cytoplasmic domains of cytokine receptors and within downstream signaling proteins such as the signal transducers and activators of transcription (STATs). Detailed analyses of tyrosine kinase substrate specificity have revealed that JAK2, like other members of the human tyrosine kinome, recognizes specific amino acid motifs surrounding the target tyrosine. Studies employing positional scanning peptide arrays and combinatorial peptide libraries have contributed to the characterization of the intrinsic substrate specificity of tyrosine kinases. For JAK kinases, the substrate motif typically spans from five residues upstream to several residues downstream of the phosphorylated tyrosine and includes preferences for particular amino acids at defined positions. For instance, the work by Yaron-Barir et al. (2024) has shown that the intrinsic substrate specificity of tyrosine kinases exhibits sequence-dependent patterns that facilitate the recognition of suitable substrates. Although the precise consensus motif for JAK2 may vary depending on the receptor context, common features include the requirement for a hydrophobic or basic residue at positions adjacent to the tyrosine residue (yaronbarir2024theintrinsicsubstrate pages 1-2, yaronbarir2024theintrinsicsubstrate pages 16-16). In cellular contexts, the docking sites formed by phosphorylated cytokine receptor tails serve as platforms that recruit STAT proteins via their SH2 domains, and subsequent phosphorylation by JAK2 further refines the substrate specificity dictated by the local peptide environment (babon2014themolecularregulation pages 7-9, yaronbarir2024theintrinsicsubstrate pages 19-22).
5. Structure  
   JAK2 is characterized by a modular architecture comprising several distinct domains that confer its catalytic activity, regulatory functions, and capacity for interactions with cytokine receptors. The protein contains an N-terminal FERM (band 4.1, ezrin, radixin, moesin) domain followed by an SH2-like domain, a pseudokinase domain (often referred to as JH2), and a C-terminal tyrosine kinase domain (JH1).  
    • The FERM domain mediates the association of JAK2 with the cytoplasmic tails of type I and II cytokine receptors and is critical for proper subcellular localization and signal initiation (babon2014themolecularregulation pages 1-3, babon2014themolecularregulation pages 3-4).  
    • The SH2-like domain, although not always functionally equivalent to classical SH2 domains in terms of phosphotyrosine binding, contributes to the structural integrity and proper positioning of adjacent domains (babon2014themolecularregulation pages 4-6, wilks2008thejakkinases pages 4-5).  
    • The pseudokinase domain (JH2) is a hallmark of JAK kinases and serves as a regulatory module that autoregulates kinase activity by inhibiting the adjacent catalytic domain in the absence of receptor stimulation. Notably, mutations in the pseudokinase domain, such as the V617F mutation, disrupt this autoinhibition and lead to constitutive activation of JAK2 activity, which is implicated in several myeloproliferative disorders (babon2014themolecularregulation pages 6-7, hubbard2018mechanisticinsightsinto pages 6-7).  
    • The C-terminal kinase domain (JH1) is the catalytically active region responsible for the phosphorylation of substrate tyrosine residues. Structural studies, including crystallography and molecular modeling, have elucidated features such as the activation loop containing key regulatory tyrosines, a hydrophobic spine, and a critical C-helix that coordinates proper catalytic conformation (babon2014themolecularregulation pages 4-6, wilks2008thejakkinases pages 4-5).  
   In addition, JAK2 exhibits unique structural features such as an insertion loop not commonly found in other tyrosine kinases and specific interdomain interfaces that mediate autoinhibition and activation. These structural hallmarks have been further delineated by X-ray crystallographic analyses and AlphaFold models, contributing to our understanding of how conformational changes upon receptor dimerization enable trans-phosphorylation and full kinase activation (wilks2008thejakkinases pages 5-6, babon2014themolecularregulation pages 26-28).
6. Regulation  
   The regulation of JAK2 activity is multifaceted and includes several layers of control mediated by post-translational modifications, domain-domain interactions, and adaptor proteins. Autophosphorylation events are central to JAK2 activation; for example, phosphorylation of tyrosines in the activation loop of the kinase domain (such as Y1007 and Y1008) is essential for enhancing catalytic activity (babon2014themolecularregulation pages 9-11, hubbard2018mechanisticinsightsinto pages 1-2). The pseudokinase domain (JH2), despite being catalytically weak, can autophosphorylate inhibitory residues such as Ser523 and Tyr570, thereby providing a negative feedback mechanism and modulating the overall kinase activity (babon2014themolecularregulation pages 6-7, hammaren2016nucleotidebindingmechanismsin pages 6-8).  
   In addition, JAK2 is subject to regulation by other post-translational modifications, including ubiquitination and SUMOylation. Ubiquitination of JAK2 has been shown to be linked to its phosphorylation state and is involved in proper turnover and signaling attenuation (ungureanu2005posttranslationalmodificationsin pages 11-14, ungureanu2005posttranslationalmodificationsin pages 16-18). Specific E3 ubiquitin ligases have been implicated in targeting activated JAK2 for proteasomal degradation, although the particular ligases have not been exhaustively defined in these reports. SUMOylation events may also influence the subcellular distribution of JAK2, including its nucleo-cytoplasmic shuttling (ungureanu2005posttranslationalmodificationsin pages 38-40, ungureanu2005posttranslationalmodificationsin pages 40-42).  
   Regulatory interactions with adaptor proteins further modulate JAK2 activity. For example, the adaptor protein Lnk binds to a specific phosphotyrosine within a linker region of JAK2, thereby negatively regulating cytokine signaling and modulating hematopoiesis (babon2014themolecularregulation pages 13-14, babon2014themolecularregulation pages 22-23). Moreover, phosphatases such as SHP1, SHP2, and PTP1B are involved in dephosphorylating activated tyrosine residues on JAK2, contributing to signal termination and maintenance of controlled cellular responses (babon2014themolecularregulation pages 15-17, ungureanu2005posttranslationalmodificationsin pages 63-65). Collectively, these regulatory mechanisms ensure that JAK2 activity is tightly controlled, permitting rapid activation in response to cytokine binding while preventing aberrant signaling that could lead to pathological outcomes (hubard2018mechanisticinsightsinto pages 2-3, babon2014themolecularregulation pages 17-18).
7. Function  
   JAK2 functions as a central non-receptor tyrosine kinase in nearly all cells expressing cytokine receptors. In the cytoplasm, it is recruited to type I and type II cytokine receptors, where it becomes activated following ligand-induced receptor dimerization. Once activated, JAK2 phosphorylates tyrosine residues on the receptor’s intracellular domains, thereby creating docking sites for STAT (signal transducer and activator of transcription) proteins (alexander2015theconciseguide pages 10-13, babon2014themolecularregulation pages 1-3). Following recruitment, STAT proteins are phosphorylated by JAK2, undergo dimerization, and translocate to the nucleus where they modulate the transcription of genes essential for processes such as cell growth, differentiation, and survival (babon2014themolecularregulation pages 13-14, hubbard2018mechanisticinsightsinto pages 1-2).  
   In addition, JAK2 plays a pivotal role in hematopoiesis. For instance, erythropoietin binding to its receptor (EPOR) leads to JAK2 activation, which in turn phosphorylates STAT5, driving the transcription of genes required for erythroid cell proliferation and differentiation (alexander2015theconciseguide pages 10-13, babon2014themolecularregulation pages 28-29). Beyond hematopoiesis, JAK2 is involved in the signaling cascades initiated by receptors for growth hormone (GHR), prolactin (PRLR), leptin (LEPR), thrombopoietin (MPL/TPOR), interferons (IFN‑α, IFN‑β, IFN‑γ), and various interleukins. These signaling events are critical for both innate and adaptive immune responses (alexander2015theconciseguide pages 10-13, babon2014themolecularregulation pages 22-23).  
   Furthermore, nuclear functions of JAK2 have been reported; once translocated into the nucleus, JAK2 phosphorylates histone H3 at tyrosine 41 (H3Y41), which results in the displacement of chromatin-associated proteins such as CBX5 (HP1 alpha) and thereby facilitates gene transcription (alexander2015theconciseguide pages 10-13). JAK2 also participates in cell cycle regulation by phosphorylating cell cycle regulators, including CDKN1B, and cooperates with other kinases such as TEC to mediate transcriptional activation of genes like FOS (alexander2015theconciseguide pages 10-13, babon2014themolecularregulation pages 17-18). These multiple biological roles underscore the multifunctional nature of JAK2 in modulating diverse cellular processes through its activity in the cytoplasm and nucleus (babon2014themolecularregulation pages 13-14, hubbard2018mechanisticinsightsinto pages 1-2).
8. Other Comments  
   Numerous small-molecule inhibitors have been developed targeting JAK2 owing to its critical involvement in cytokine signaling and its association with various diseases, most notably myeloproliferative neoplasms and certain leukemias. Specific inhibitors listed in the literature include agents such as NS-018, BMS-911543, AT-9283, XL019, fedratinib, and gandotinib, all designed to inhibit aberrant JAK2 activity (alexander2015theconciseguide pages 10-13, wilks2008thejakkinases pages 8-9). Ruxolitinib, although initially characterized as a JAK1-selective inhibitor, also exhibits clinical efficacy against JAK2-driven pathologies. The commonly observed JAK2V617F mutation, which leads to constitutive kinase activation, is frequently targeted by these therapeutic agents, and its presence is strongly correlated with myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis (babon2014themolecularregulation pages 6-7, wilks2008thejakkinases pages 9-10).  
   In addition to direct kinase inhibition, efforts to modulate JAK2 activity also include strategies aimed at interfering with its protein–protein interactions, such as those between the FERM domain and the receptor, or by stabilizing the autoinhibitory interaction between the pseudokinase (JH2) and kinase (JH1) domains. Disease associations extend beyond hematologic malignancies to include roles in immune dysregulation and possibly in signaling cascades involved in metabolic regulation. The extensive efforts to develop selective JAK2 inhibitors are supported by detailed structural studies and substrate specificity analyses, including recent contributions that outline the intrinsic substrate specificity of the tyrosine kinome (yaronbarir2024theintrinsicsubstrate pages 1-2, babon2014themolecularregulation pages 22-23).  
   Finally, JAK2 stands as a prominent target in drug discovery pipelines, and resources such as the Chemical Probes portal, the MRC Kinase Inhibitor Database, and others are routinely consulted to assess inhibitor specificity and efficacy against this kinase (leoni2014novelthiazolederivatives pages 6-7, bansal2023smallmoleculeinhibitorsof pages 2-3).
9. References  
   • alexander2015theconciseguide pages 10-13  
   • babon2014themolecularregulation pages 1-3  
   • babon2014themolecularregulation pages 3-4  
   • babon2014themolecularregulation pages 4-6  
   • babon2014themolecularregulation pages 6-7  
   • babon2014themolecularregulation pages 7-9  
   • babon2014themolecularregulation pages 9-11  
   • babon2014themolecularregulation pages 11-13  
   • babon2014themolecularregulation pages 13-14  
   • babon2014themolecularregulation pages 14-15  
   • babon2014themolecularregulation pages 15-17  
   • babon2014themolecularregulation pages 17-18  
   • babon2014themolecularregulation pages 18-19  
   • babon2014themolecularregulation pages 22-23  
   • babon2014themolecularregulation pages 26-28  
   • babon2014themolecularregulation pages 28-29  
   • hubbard2018mechanisticinsightsinto pages 1-2  
   • hubbard2018mechanisticinsightsinto pages 2-3  
   • hubbard2018mechanisticinsightsinto pages 3-5  
   • hubbard2018mechanisticinsightsinto pages 5-6  
   • hubbard2018mechanisticinsightsinto pages 6-7  
   • hammaren2016nucleotidebindingmechanismsin pages 5-6  
   • hammaren2016nucleotidebindingmechanismsin pages 6-8  
   • krupa2002therepertoireof pages 5-7  
   • ungureanu2005posttranslationalmodificationsin pages 9-11  
   • ungureanu2005posttranslationalmodificationsin pages 11-14  
   • ungureanu2005posttranslationalmodificationsin pages 14-16  
   • ungureanu2005posttranslationalmodificationsin pages 16-18  
   • ungureanu2005posttranslationalmodificationsin pages 38-40  
   • ungureanu2005posttranslationalmodificationsin pages 40-42  
   • ungureanu2005posttranslationalmodificationsin pages 63-65  
   • ungureanu2005posttranslationalmodificationsin pages 65-68  
   • wilks2008thejakkinases pages 1-1  
   • wilks2008thejakkinases pages 1-3  
   • wilks2008thejakkinases pages 3-4  
   • wilks2008thejakkinases pages 4-5  
   • wilks2008thejakkinases pages 5-6  
   • wilks2008thejakkinases pages 6-8  
   • wilks2008thejakkinases pages 8-9  
   • wilks2008thejakkinases pages 9-9  
   • wilks2008thejakkinases pages 9-10  
   • yaronbarir2024theintrinsicsubstrate pages 1-2  
   • yaronbarir2024theintrinsicsubstrate pages 16-16  
   • yaronbarir2024theintrinsicsubstrate pages 19-22  
   • bansal2023smallmoleculeinhibitorsof pages 2-3  
   • blazquez2020potentialforprotein pages 1-2  
   • boudeau2006emergingrolesof pages 1-2

References

1. (alexander2015theconciseguide pages 10-13): Stephen PH Alexander, Doriano Fabbro, Eamonn Kelly, Neil Marrion, John A Peters, Helen E Benson, Elena Faccenda, Adam J Pawson, Joanna L Sharman, Christopher Southan, and Jamie A Davies. The concise guide to pharmacology 2015/16: enzymes. British Journal of Pharmacology, 172:6024-6109, Dec 2015. URL: https://doi.org/10.1111/bph.13354, doi:10.1111/bph.13354. This article has 577 citations and is from a highest quality peer-reviewed journal.
2. (babon2014themolecularregulation pages 1-3): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
3. (babon2014themolecularregulation pages 13-14): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
4. (babon2014themolecularregulation pages 14-15): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
5. (babon2014themolecularregulation pages 17-18): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
6. (babon2014themolecularregulation pages 18-19): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
7. (babon2014themolecularregulation pages 26-28): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
8. (babon2014themolecularregulation pages 4-6): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
9. (babon2014themolecularregulation pages 6-7): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
10. (babon2014themolecularregulation pages 9-11): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
11. (hubbard2018mechanisticinsightsinto pages 1-2): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
12. (hubbard2018mechanisticinsightsinto pages 5-6): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
13. (hubbard2018mechanisticinsightsinto pages 6-7): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
14. (ungureanu2005posttranslationalmodificationsin pages 11-14): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
15. (wilks2008thejakkinases pages 3-4): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
16. (wilks2008thejakkinases pages 6-8): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
17. (babon2014themolecularregulation pages 11-13): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
18. (babon2014themolecularregulation pages 15-17): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
19. (babon2014themolecularregulation pages 3-4): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
20. (babon2014themolecularregulation pages 7-9): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
21. (hammaren2016nucleotidebindingmechanismsin pages 6-8): Henrik M. Hammarén, Anniina T. Virtanen, and Olli Silvennoinen. Nucleotide-binding mechanisms in pseudokinases. Bioscience Reports, Jan 2016. URL: https://doi.org/10.1042/bsr20150226, doi:10.1042/bsr20150226. This article has 49 citations and is from a peer-reviewed journal.
22. (hubbard2018mechanisticinsightsinto pages 3-5): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
23. (ungureanu2005posttranslationalmodificationsin pages 14-16): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
24. (ungureanu2005posttranslationalmodificationsin pages 16-18): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
25. (ungureanu2005posttranslationalmodificationsin pages 38-40): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
26. (ungureanu2005posttranslationalmodificationsin pages 40-42): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
27. (ungureanu2005posttranslationalmodificationsin pages 63-65): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
28. (ungureanu2005posttranslationalmodificationsin pages 65-68): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
29. (ungureanu2005posttranslationalmodificationsin pages 9-11): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
30. (wilks2008thejakkinases pages 1-1): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
31. (wilks2008thejakkinases pages 1-3): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
32. (wilks2008thejakkinases pages 4-5): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
33. (wilks2008thejakkinases pages 5-6): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
34. (wilks2008thejakkinases pages 8-9): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
35. (wilks2008thejakkinases pages 9-10): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
36. (wilks2008thejakkinases pages 9-9): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 123 citations.
37. (yaronbarir2024theintrinsicsubstrate pages 1-2): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 50 citations and is from a highest quality peer-reviewed journal.
38. (yaronbarir2024theintrinsicsubstrate pages 16-16): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 50 citations and is from a highest quality peer-reviewed journal.
39. (yaronbarir2024theintrinsicsubstrate pages 19-22): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 50 citations and is from a highest quality peer-reviewed journal.
40. (babon2014themolecularregulation pages 22-23): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
41. (babon2014themolecularregulation pages 28-29): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
42. (bansal2023smallmoleculeinhibitorsof pages 2-3): Isha Bansal, Amit Kumar Pandey, and Munindra Ruwali. Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges. Frontiers in Pharmacology, Aug 2023. URL: https://doi.org/10.3389/fphar.2023.1244597, doi:10.3389/fphar.2023.1244597. This article has 10 citations and is from a peer-reviewed journal.
43. (blazquez2020potentialforprotein pages 1-2): Ana-Belén Blázquez and Juan-Carlos Saiz. Potential for protein kinase pharmacological regulation in flaviviridae infections. International Journal of Molecular Sciences, 21:9524, Dec 2020. URL: https://doi.org/10.3390/ijms21249524, doi:10.3390/ijms21249524. This article has 15 citations and is from a peer-reviewed journal.
44. (boudeau2006emergingrolesof pages 1-2): Jérôme Boudeau, Diego Miranda-Saavedra, Geoffrey J. Barton, and Dario R. Alessi. Emerging roles of pseudokinases. Trends in Cell Biology, 16:443-452, Sep 2006. URL: https://doi.org/10.1016/j.tcb.2006.07.003, doi:10.1016/j.tcb.2006.07.003. This article has 646 citations and is from a domain leading peer-reviewed journal.
45. (hammaren2016nucleotidebindingmechanismsin pages 5-6): Henrik M. Hammarén, Anniina T. Virtanen, and Olli Silvennoinen. Nucleotide-binding mechanisms in pseudokinases. Bioscience Reports, Jan 2016. URL: https://doi.org/10.1042/bsr20150226, doi:10.1042/bsr20150226. This article has 49 citations and is from a peer-reviewed journal.
46. (hubbard2018mechanisticinsightsinto pages 2-3): Stevan R. Hubbard. Mechanistic insights into regulation of jak2 tyrosine kinase. Frontiers in Endocrinology, Jan 2018. URL: https://doi.org/10.3389/fendo.2017.00361, doi:10.3389/fendo.2017.00361. This article has 118 citations and is from a peer-reviewed journal.
47. (krupa2002therepertoireof pages 5-7): A. Krupa and N. Srinivasan. The repertoire of protein kinases encoded in the draft version of the human genome: atypical variations and uncommon domain combinations. Genome Biology, 3:research0066.1-research0066.14, Nov 2002. URL: https://doi.org/10.1186/gb-2002-3-12-research0066, doi:10.1186/gb-2002-3-12-research0066. This article has 68 citations and is from a highest quality peer-reviewed journal.
48. (leoni2014novelthiazolederivatives pages 6-7): Alberto Leoni, Alessandra Locatelli, Rita Morigi, and Mirella Rambaldi. Novel thiazole derivatives: a patent review (2008 – 2012; part 1). Expert Opinion on Therapeutic Patents, 24:201-216, Jan 2014. URL: https://doi.org/10.1517/13543776.2014.858121, doi:10.1517/13543776.2014.858121. This article has 78 citations and is from a peer-reviewed journal.